Drug Trial Radar · NCT05145569
Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jan 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 10, 2024
Primary completion
May 31, 2026
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Haider MahdiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- HCW Biologics
- First posted
- Dec 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, the safety, tolerability, and anti-tumor activity of HCW9218 in combination with chemotherapy will be assessed in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy.
Conditions
- Ovarian Cancer
Interventions
Carboplatin AUC 5 and paclitaxelDrug
Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
HCW9218Drug
HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Dose Limiting Toxicities (DLT)Time frame: Up to 8 weeks
- Adverse Events Related to TreatmentTime frame: Up to 12 months
- Complete Pathologic ResponseTime frame: Up to 36 months
- CD8+ T-cell characterizationTime frame: Up to 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.